

~ Updates on HPMS Memos ~

<b>CMS Memo Title &amp; Release Date</b>	2022 Performance Measure Validation Requirements for Medicare-Medicaid Plans – Dated 05/19/2022
<b>Summary</b>	CMS will perform the 2022 Performance Measure Validation (PMV) cycle for ongoing performance measure validation of select core and state-specific measures to ensure the reported data are reliable, valid. Complete, and comparable among Medicare-Medicaid Plans.
<b>Action - PACE</b>	Informational to PACE. Refer to the email for complete details.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Updates to COVID-19 Sharing Projects – Dated 05/19/2022
<b>Summary</b>	<p>CMS announces effective <b>July 1, 2022</b>, the COVAX data sharing projects will implement the following changes:</p> <p><b>Source of Data Provided in ABII-COVAX.</b> New NCPDP pharmacy data will not be used to generate the COVID-19 Vaccinated Beneficiaries Report provided through the ABIICOVAX Web Portal. Medicare Shared Systems Data will be the sole data source used to generate the COVID-19 Vaccinated Beneficiaries Report. Since these reports present cumulative observations, they will continue to include historical NCPDP data received through June 30, 2022.</p> <p><b>Direct Data Feeds from RelayHealth.</b> Plans will no longer be able to request or receive NCPDP pharmacy data directly from RelayHealth. Plans currently receiving such data that wish to continue to receive data via the ABII-COVAX Web Portal should refer to the January 28, 2022 HPMS memorandum titled “Continuation of COVID-19 Sharing Project in CY 2022”.</p>
<b>Action - PACE</b>	Applicable to PACE.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Email Title &amp; Release Date</b>	Process for Requesting an HPMS Crosswalk Exception for Contract Year 2023 – Dated 05/25/2022
<b>Summary</b>	CMS announces an additional opportunity to request HPMS crosswalk exceptions for CY 2023 from <b>Tuesday, June 7<sup>th</sup>, 2022 through Wednesday, June 8<sup>th</sup>, 2022 at 5:00 p.m. ET</b> via HPMS.

<b>Action - PACE</b>	Informational to PACE. Refer to the memo for complete details.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	State Medicaid Agency Contracts Submission Requirements for Contract Year 2023– Dated 05/26/2022
<b>Summary</b>	CMS reminds all contracts seeking to offer a Dual Eligible Special Needs Plan (D-SNP) for contract year 2023 to complete the necessary attestations, upload State Medicaid Agency Contracts (SMACs) along with any other supporting documentation in HPMS by <b>July 5th, 2022 at 8 PM ET</b> . Refer to memo for pathway.
<b>Action - PACE</b>	Informational to PACE. Refer to memo to determine if this may be applicable to your plan.
<b>Action - MAPD</b>	Refer to memo if this may be applicable to your plan.
<b>CMS Email Title &amp; Release Date</b>	Contract Year (CY) 2023 Bid Outlier Justification Training – Dated 05/27/2022
<b>Summary</b>	CMS announces the release of the HPMS 2023 Bid Outlier Justification Training for the Part D benefits review functionality. CMS conducts this process for CY 2023 with two Part D sub-reviews: crosscheck and PDP meaningful difference. This training provides Part D users with a walkthrough of the new Bid Outlier Justification module including how to review and respond to potential benefits review concerns.
<b>Action - PACE</b>	Applicable to PACE.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	CY 2023 Bid Review Out-of-Pocket Cost Models - New Generic Drugs - Dated 05/31/2022
<b>Summary</b>	CMS issued the CY 2023 Bid Review Out-of-Pocket Cost (OOPC) Model on April 8, 2022, based on the March CY 2023 Formulary Reference File (FRF). This was consistent with prior plan years, where the model that CMS makes available for the bid review is based on the March FRF, the initial FRF for that plan year. For the CY 2023 model, CMS is aware that some new generic drugs that were unable to be incorporated as substitutes in the model have a significant impact on OOPC calculations. CMS is creating an updated OOPC model that will be used during the review process to account for coverage of generics that were newly available on the May CY 2023 FRF.
<b>Action - PACE</b>	Informational to PACE as PACE is waived of the out-of-pocket provisions.
<b>Action - MAPD</b>	Applicable to MAPD.

<b>CMS Memo Title &amp; Release Date</b>	Contract Year (CY) 2023 Part D Pricing Data Submission Guidance – Dated 05/31/2022
<b>Summary</b>	CMS released information on Contract Year (CY) 2023 guidance and a schedule for submission of the pricing and pharmacy data through the HPMS module for posting on the Medicare Plan Finder. The module will be available to plans on July 1, 2022 for the first official CY 2023 pricing file test window.
<b>Action - PACE</b>	Informational to PACE plans who utilize a formulary. Refer to the memo for complete details.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Release of Medical Loss Ratio (MLR) Data Form and Filing Instructions for Contract Year 2021 – Dated 05/31/2022
<b>Summary</b>	CMS released the MLR Data Form and filing instructions for CY 2021 which is available in HPMS on June 2 <sup>nd</sup> , 2022 and must be submitted by February 3, 2023. The electronic attestation functionality for CY 2021 MLR will be available on February 6th, 2023 and must be submitted by February 15th, 2023.
<b>Action - PACE</b>	Informational to PACE as the MLR provision does not apply.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Proposed Updates to the Prescription Drug Event (PDE) File Layout; Seeking Feedback – Dated 05/31/2022
<b>Summary</b>	<p>The purpose of this memo is to seek plan feedback regarding anticipated updates to the PDE file size and layout. CMS is planning to expand the PDE file layout from its current 512-byte length to 1000 bytes as well as add the fields listed below:</p> <ul style="list-style-type: none"> <li>• Original Quantity Prescribed</li> <li>• Patient Liability Reduction due to EGWP</li> <li>• Pharmacy Price Concessions at POS</li> <li>• LTPAC Dispense Frequency</li> <li>• Updates to Existing Fields <ul style="list-style-type: none"> <li>○ Product Service ID</li> <li>○ Prescriber ID</li> <li>○ Estimated Remuneration at POS</li> <li>○ Vaccine Administration Fee</li> <li>○ Dollar Amount Fields</li> </ul> </li> </ul> <p>Refer to memo for full details. An email address is provided if your plan would like to provide feedback.</p>
<b>Action - PACE</b>	Applicable to PACE. Pharmastar will pursue the certification process.

<b>Action - MAPD</b>	Applicable to MAPD. Pharmastar will pursue the certification process.
<b>CMS Memo Title &amp; Release Date</b>	CY2023 Initial Actuarial Certification Deadline – Dated 06/01/2022
<b>Summary</b>	As part of the CY 2023 bid submission requirements, an actuarial certification must be submitted via the HPMS actuarial certification module for every Bid Pricing Tool uploaded to HPMS. All initial certifications are to be completed by Friday, June 10th, 2022. If a certification is not submitted via HPMS, the bid(s) will not be considered for CMS review or approval.
<b>Action - PACE</b>	Informational to PACE. PACE plans should review the status of this requirement with their respective actuaries.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Medicare Advantage/Prescription Drug System (MARx) June 2022 Payment - INFORMATION – Dated 05/27/2022
<b>Summary</b>	CMS released information about the October payment which is scheduled for June 1 <sup>st</sup> , 2022 and may require plan action on the following: <ul style="list-style-type: none"> <li>• 2021 Interim Final Risk Adjustment Reconciliation</li> <li>• Coverage Gap Discount (CGD) Invoice Offsets</li> <li>• Sequestration Suspension</li> <li>• 2022 Frailty Score Update</li> <li>• Changes to MARx Plan Transaction Processing</li> </ul>
<b>Action - PACE</b>	Applicable to PACE.
<b>Action - MAPD</b>	Applicable to MAPD.

**For the latest CMS response to COVID-19, please visit the [CMS.gov](https://www.cms.gov) website.**

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.